NIH exercises a $5.27 million option on Locus Biosciences contract

USAspending records a $5,271,052 option exercised on October 16, 2026 under Locus Biosciences’ NIAID contract 75N93025C00035, bringing total obligations to $13,166,917. This is a contract-funding action, separate from the company’s January $3.3 million announcement; it does not establish clinical-trial results.